BridgeBio Pharma (BBIO) Restructuring Costs (2022 - 2025)
BridgeBio Pharma (BBIO) posted Restructuring Costs of $11.1 million for Q4 2025, up 25.9% sequentially from $8.8 million in Q3 2025, and up 137.18% YoY from $4.7 million in Q4 2024.
BridgeBio Pharma (BBIO) Restructuring Costs (2022 - 2025) Analysis & Trends
BridgeBio Pharma has reported Restructuring Costs for 4 years, with the latest figure at $11.1 million in Q4 2025.
- Quarterly Restructuring Costs rose 137.18% year-over-year to $11.1 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $20.8 million (up 69.79% YoY) and the FY2025 annual result came in at $21.3 million, up 36.8% from the prior year.
- Restructuring Costs rose to $11.1 million in Q4 2025 per BBIO's latest filing, from $8.8 million in the prior quarter.
- Over five years, Restructuring Costs peaked at $22.7 million in Q1 2022 and troughed at $272000.0 in Q3 2023.
- A 4-year average of $5.4 million and a median of $4.1 million in 2023 frame the typical range for Restructuring Costs.
- The sharpest annual moves came in 2023 and 2024: Restructuring Costs tumbled 94.58% in 2023, then soared 1598.9% in 2024.
- Over 4 years, Restructuring Costs stood at $7.7 million in 2022, then plunged by 90.2% to $754000.0 in 2023, then soared by 522.41% to $4.7 million in 2024, then jumped by 137.18% to $11.1 million in 2025.
- According to Business Quant data, Restructuring Costs over the past three periods registered $11.1 million, $8.8 million, and $805000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | BridgeBio Pharma | 15.60 Bn | 14.89 Bn | 228.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 11.13 Mn |
| Sep 30, 2025 | 8.84 Mn |
| Jun 30, 2025 | 805,000.00 |
| Mar 31, 2025 | 570,000.00 |
| Dec 31, 2024 | 4.69 Mn |
| Sep 30, 2024 | 4.62 Mn |
| Jun 30, 2024 | 2.35 Mn |
| Mar 31, 2024 | 1.16 Mn |
| Dec 31, 2023 | 754,000.00 |
| Sep 30, 2023 | 272,000.00 |
| Jun 30, 2023 | 3.53 Mn |
| Mar 31, 2023 | 3.37 Mn |
| Dec 31, 2022 | 7.69 Mn |
| Sep 30, 2022 | 5.02 Mn |
| Jun 30, 2022 | 8.40 Mn |
| Mar 31, 2022 | 22.66 Mn |